ResMed is leveraging the popularity of Ozempic-style weight loss drugs to enhance screenings for sleep apnea, reporting ...

We came across a bullish thesis on ResMed Inc. on Best Anchor Stocks’s Substack. In this article, we will summarize the bulls ...

ResMed dominates the global sleep apnea device market, boasting a 50–60% share and a high-margin razor-razor-blade business ...

Masks and accessories were the standout growth category for Resmed in the second quarter of its fiscal year 2026, with the company reporting a 16% increase in revenue in the United States, Canada and ...

Resmed has beaten expectations with $2 billion in second-quarter revenue and says weight loss drugs are actually boosting ...

Q2 FY2026 earnings call recap: 11% revenue growth, margin expansion, AI innovation, and updated 62–63% guidance—read key takeaways now.

Revenue increased by 11% to $1.4 billion; up 9% on a constant currency basis Gross margin up 320 bps to 61.8%; non-GAAP gross margin up 310 bps ...

Medical device maker ResMed on Thursday beat Wall Street estimates for second-quarter profit on the back of strong demand for its devices used to manage sleep apnea.

(RMD) on Thursday reported fiscal second-quarter net income of $392.6 million. On a per-share basis, the San Diego-based company said it had net income ...

Sleep apnea is a serious condition, causing breathing to stop and start several times during sleep. The most common form of the condition is obstructive sleep apnea, where the throat narrows, blocking ...

The ASX healthcare sector is not exactly basking in love, despite supposedly being one of the most defensive and reliable ...

SAN DIEGO – Resmed has received clearance from the U.S. Food and Drug Administration (FDA) for an artificial intelligence (AI)-enabled device that recommends personalized comfort settings to help ...